专业监测看板

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

药物 / 成分：Abemaciclib

登记的停止原因（原文）：Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant immunotherapy.

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

药物 / 成分：BI 1569912、Placebo

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

药物 / 成分：Brexanolone Injection [Zulresso]

登记的停止原因（原文）：Loss of funding.

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

药物 / 成分：Vibecotamab、Dexamethasone、Acetaminophen、Diphenhydramine

登记的停止原因（原文）：\<75% participation

Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

药物 / 成分：Rosuvastatin 20 mg、Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]

登记的停止原因（原文）：Slow patient enrollment and lack of financial support

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

药物 / 成分：BI 1821736

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

药物 / 成分：Echocardiography Test、Ibrutinib

登记的停止原因（原文）：poor accrual

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

药物 / 成分：BG-60366

登记的停止原因（原文）：Evaluation on business strategy, not involving safety issue.

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

药物 / 成分：PF-07985045、Gemcitabine、Nab-paclitaxel、Cetuximab

登记的停止原因（原文）：The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.

Tralokinumab for Dupilumab Failures

药物 / 成分：tralokinumab

登记的停止原因（原文）：Principal Investigator retired

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

药物 / 成分：GS3-007a dry suspension、Insulin

登记的停止原因（原文）：Adjustment of sponsor's product development strategy.

Tivozanib + Enzalutamide in Adv Prostate Cancer

药物 / 成分：Tivozanib、Enzalutamide

登记的停止原因（原文）：Slow accrual

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

药物 / 成分：Fludarabine、Cyclophosphamide、Total Body Irradiation、Cyclosporine A

登记的停止原因（原文）：No longer a research question to answer.

Adjunctive Gypenosides for Acute Optic Neuritis

药物 / 成分：Gypenosides、Placebo

登记的停止原因（原文）：Slow recruitment and an unexpectedly high proportion of AQP4-IgG-positive optic neuritis on masked feasibility review limited feasibility. No interim efficacy analysis was performed.

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

药物 / 成分：TOL-3021、TOL-3021 Placebo

登记的停止原因（原文）：The DSMB concluded that there was a low probability the study would meet it is primary endpoint as designed.

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

药物 / 成分：Naproxen Sodium、Placebo

登记的停止原因（原文）：Low recruitment

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

药物 / 成分：Biospecimen Collection、Computed Tomography、Magnetic Resonance Imaging、Memantine

登记的停止原因（原文）：Inadequate accrual rate

Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

药物 / 成分：Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)、Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)、Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)、Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)

登记的停止原因（原文）：Data generated in the Gates MRI-TBD06-201 trial do not support the investigational regimens being able to achieve the trial objective of identifying a new regimen to treat tuberculosis in 3 months or less.

Upadacitinib for Prurigo Nodularis

药物 / 成分：Upadacitinib

登记的停止原因（原文）：There was not a big enough patient population to meet recruitment goals

Mechanisms of Hypoglycemia Associated Autonomic Failure

药物 / 成分：naloxone、fructose、exercise、Morphine sulfate

登记的停止原因（原文）：Protocol was terminated due to enrollment + feasibility issues. Aim 2 not conducted. Aims 1 + 3 were conducted in part. During Aim 3 the IRB requested that the study be transitioned under a new protocol (2018-9208) in order to simplify reporting.